Lorus Therapeutics Inc. has announced the presentation of positive nonclinical toxicity data for its lead small molecule anti-cancer drug candidate LOR-253 at the Annual Meeting of the American College of Toxicology (ACT).
The ACT Annual Meeting taking place in Phoenix, Arizona, November 6-9, is one of the largest and most respected toxicology conferences held globally each year.
The poster presentation details the results of nonclinical toxicity and toxicokinetics studies conducted with LOR-253.
The studies were part of the formal safety evaluation of LOR-253 to support first-in-man clinical trials in cancer, and to determine the starting dose of LOR-253 in patients.
The studies, which took place over one year, examined a wide range of toxicity parameters in rat and dog species, as well as safety pharmacology and blood toxicity.
Overall, LOR-253 had a favorable nonclinical toxicology profile in both animal species and was well tolerated at doses higher than efficacious dose levels established in animal models of human cancers.
Of significance, the data show that the effective dose could be increased by a factor of eight to fifteen before seeing levels of toxicity in the animal studies.
Additional data in the poster include the results of preclinical anticancer studies on LOR-253 in mouse models of human non-small cell lung cancer (NSCLC).
The data show that LOR-253 has significant anticancer activity against NSCLC, particularly in tumors with low expression levels of the tumor suppressor Kruppel-like factor 4 (KLF4).
Lorus is currently examining the role of KLF4 as a potential biomarker for LOR-253 anticancer activity.
The poster, entitled "Nonclinical Toxicity Studies for a Novel Anticancer Agent, LOR-253" (Abstract No. 701), will be presented on November 8, 2011 by Intrinsik Health Sciences Inc., a leading provider of toxicology and regulatory affairs consulting services that collaborated with Lorus on the LOR-253 toxicity program.
"We're very pleased to have our formal nonclinical toxicity data for LOR-253 presented at a major toxicology conference", said Dr. Aiping Young, Lorus' President and CEO.
Dr. Young continued, "We're grateful to Intrinsik Health Sciences for presenting the data, and for their expert guidance and input on this program."